Clinical Trial Update: Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy [Phase 4]

View source ↗

Summary

A Phase 4 study of Natalizumab (Tysabri) for Crohn's disease in patients who failed anti-TNF-α therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Crohn's Disease | Phase 4 | Status: WITHDRAWN